These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32616363)

  • 1. Pyrostigmine therapy in a patient with VAMP1-related congenital myasthenic syndrome.
    Al-Muhaizea MA; AlQuait L; AlRasheed A; AlHarbi S; Albader AA; AlMass R; Albakheet A; Alhumaidan A; AlRasheed MM; Colak D; Kaya N
    Neuromuscul Disord; 2020 Jul; 30(7):611-615. PubMed ID: 32616363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the genetic and phenotypic spectrum of congenital myasthenic syndrome: new homozygous VAMP1 splicing variants in 2 novel individuals.
    Cotrina-Vinagre FJ; Rodríguez-García ME; Del Pozo-Filíu L; Hernández-Laín A; Arteche-López A; Morte B; Sevilla M; Pérez-Jurado LA; Quijada-Fraile P; Camacho A; Martínez-Azorín F
    J Hum Genet; 2024 May; 69(5):187-196. PubMed ID: 38355957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VAMP1-Related Congenital Myasthenic Syndrome: A Case Report and Literature Review.
    Yıldırım M; Yarenci GB; Genç MB; Uçar Çİ; Bayav S; Tekin MN; Bektaş Ö; Teber S
    Neuropediatrics; 2024 Jun; 55(3):200-204. PubMed ID: 38531369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous mutations in VAMP1 cause a presynaptic congenital myasthenic syndrome.
    Salpietro V; Lin W; Delle Vedove A; Storbeck M; Liu Y; Efthymiou S; Manole A; Wiethoff S; Ye Q; Saggar A; McElreavey K; Krishnakumar SS; ; Pitt M; Bello OD; Rothman JE; Basel-Vanagaite L; Hubshman MW; Aharoni S; Manzur AY; Wirth B; Houlden H
    Ann Neurol; 2017 Apr; 81(4):597-603. PubMed ID: 28253535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recessive VAMP1 mutations associated with severe congenital myasthenic syndromes - A recognizable clinical phenotype.
    Polavarapu K; Vengalil S; Preethish-Kumar V; Arunachal G; Nashi S; Mohan D; Chawla T; Bardhan M; Nandeesh B; Gupta P; Gowda VK; Lochmüller H; Nalini A
    Eur J Paediatr Neurol; 2021 Mar; 31():54-60. PubMed ID: 33631708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing the Understanding of Vesicle-Associated Membrane Protein 1-Related Congenital Myasthenic Syndrome: Phenotypic Insights, Favorable Response to 3,4-Diaminopyridine, and Clinical Characterization of Five New Cases.
    Natera-de Benito D; Pugliese A; Polavarapu K; Guergueltcheva V; Tournev I; Todorova A; Afonso Ribeiro J; Fernández-Mayoralas DM; Ortez C; Martorell L; Estévez-Arias B; Matalonga L; Laurie S; Jou C; Lau J; Thompson R; Shen X; Engel AG; Nascimento A; Lochmüller H; Selcen D
    Pediatr Neurol; 2024 Aug; 157():5-13. PubMed ID: 38833907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique presentation of rapidly fluctuating symptoms in a child with congenital myasthenic syndrome due to RAPSN mutation.
    Kumar A; Asghar S; Kavanagh R; Wicklund MP
    Muscle Nerve; 2018 Oct; 58(4):E23-E24. PubMed ID: 30028532
    [No Abstract]   [Full Text] [Related]  

  • 8. How to Spot Congenital Myasthenic Syndromes Resembling the Lambert-Eaton Myasthenic Syndrome? A Brief Review of Clinical, Electrophysiological, and Genetics Features.
    Lorenzoni PJ; Scola RH; Kay CSK; Werneck LC; Horvath R; Lochmüller H
    Neuromolecular Med; 2018 Jun; 20(2):205-214. PubMed ID: 29696584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Neuromuscular Junction and Wide Heterogeneity of Congenital Myasthenic Syndromes.
    Rodríguez Cruz PM; Palace J; Beeson D
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29874875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and neurophysiological response to ephedrine in a patient affected with slow-channel congenital myasthenic syndrome.
    Eirís-Puñal J; Fuentes-Pita P; Gómez-Lado C; Pérez-Gay L; López-Vázquez A; Quintas-Rey R; Barros-Angueira F; Pardo J
    Rev Neurol; 2020 Sep; 71(6):221-224. PubMed ID: 32895905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recessive congenital myasthenic syndrome caused by a homozygous mutation in SYT2 altering a highly conserved C-terminal amino acid sequence.
    Maselli RA; van der Linden H; Ferns M
    Am J Med Genet A; 2020 Jul; 182(7):1744-1749. PubMed ID: 32250532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biallelic loss of function variants in SYT2 cause a treatable congenital onset presynaptic myasthenic syndrome.
    Donkervoort S; Mohassel P; Laugwitz L; Zaki MS; Kamsteeg EJ; Maroofian R; Chao KR; Verschuuren-Bemelmans CC; Horber V; Fock AJM; McCarty RM; Jain MS; Biancavilla V; McMacken G; Nalls M; Voermans NC; Elbendary HM; Snyder M; Cai C; Lehky TJ; Stanley V; Iannaccone ST; Foley AR; Lochmüller H; Gleeson J; Houlden H; Haack TB; Horvath R; Bönnemann CG
    Am J Med Genet A; 2020 Oct; 182(10):2272-2283. PubMed ID: 32776697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
    Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
    Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel PLEC gene variants causing congenital myasthenic syndrome.
    Gonzalez Garcia A; Tutmaher MS; Upadhyayula SR; Sanchez Russo R; Verma S
    Muscle Nerve; 2019 Dec; 60(6):E40-E43. PubMed ID: 31509265
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome.
    Rizvi M; Truong TK; Zhou J; Batta M; Moran ES; Pappas J; Chu ML; Caluseriu O; Evrony GD; Leslie EM; Cordat E
    Hum Mol Genet; 2023 Apr; 32(9):1552-1564. PubMed ID: 36611016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family.
    Matlik HN; Milhem RM; Saadeldin IY; Al-Jaibeji HS; Al-Gazali L; Ali BR
    Pediatr Neurol; 2014 Jul; 51(1):165-9. PubMed ID: 24938146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congenital myasthenic syndrome in Turkey: clinical and genetic features in the long-term follow-up of patients.
    Gül Mert G; Özcan N; Hergüner Ö; Altunbaşak Ş; Incecik F; Bişgin A; Ceylaner S
    Acta Neurol Belg; 2021 Apr; 121(2):529-534. PubMed ID: 31773638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital myasthenic syndrome due to a genetic mutation.
    Tsalta-Mladenov M; Levkova M; Georgieva D; Andonova S
    J Am Assoc Nurse Pract; 2023 Aug; 35(8):519-523. PubMed ID: 37141567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
    Tsao CY
    Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital Myasthenic Syndromes.
    Iyadurai SJP
    Neurol Clin; 2020 Aug; 38(3):541-552. PubMed ID: 32703467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.